PMID- 23525524
OWN - NLM
STAT- MEDLINE
DCOM- 20140210
LR  - 20211021
IS  - 1432-2072 (Electronic)
IS  - 0033-3158 (Print)
IS  - 0033-3158 (Linking)
VI  - 228
IP  - 2
DP  - 2013 Jul
TI  - Serotonergic hallucinogens differentially modify gamma and high frequency 
      oscillations in the rat nucleus accumbens.
PG  - 271-82
LID - 10.1007/s00213-013-3057-1 [doi]
AB  - RATIONALE: The nucleus accumbens (NAc) is a site critical for the actions of many 
      drugs of abuse. Psychoactive compounds, such as N-methyl-D-aspartate receptor 
      (NMDAR) antagonists, modify gamma (40-90) and high frequency oscillations (HFO, 
      130-180 Hz) in local field potentials (LFPs) recorded in the NAc. Lysergic acid 
      diethylamide (LSD) and 2,5-dimethoxy-4-iodoamphetamine (DOI) are serotonergic 
      hallucinogens and activation of 5HT2A receptors likely underlies their 
      hallucinogenic effects. Whether these compounds can also modulate LFP 
      oscillations in the NAc is unclear. OBJECTIVE: This study aims to examine the 
      effect of serotonergic hallucinogens on gamma and HFO recorded in the NAc and to 
      test whether 5HT2A receptors mediate the effects observed. METHODS: LFPs were 
      recorded from the NAc of freely moving rats. Drugs were administered 
      intraperitoneally. RESULTS: LSD (0.03-0.3 mg/kg) and DOI (0.5-2.0 mg/kg) 
      increased the power and reduced the frequency of HFO. In contrast, the 
      hallucinogens produced a robust reduction in the power of low (40-60 Hz), but not 
      high gamma oscillations (70-90 Hz). MDL 11939 (1.0 mg/kg), a 5HT2A receptor 
      antagonist, fully reversed the changes induced by DOI on HFO but only partially 
      for the low gamma band. Equivalent increases in HFO power were observed after 
      TCB-2 (5HT2A receptor agonist, 0.1-1.5 mg/kg), but not CP 809101 (5H2C receptor 
      agonist, 0.1-3 mg/kg). Notably, hallucinogen-induced increases in HFO power were 
      smaller than those produced by ketamine (25 mg/kg). CONCLUSIONS: Serotonergic 
      hallucinogen-induced changes in HFO and gamma are mediated, at least in part, by 
      stimulation of 5HT2A receptors. Comparison of the oscillatory changes produced by 
      serotonergic hallucinogens and NMDAR antagonists are also discussed.
FAU - Goda, Sailaja A
AU  - Goda SA
AD  - Laboratory of the Limbic System, Nencki Institute of Experimental Biology, 3 
      Pasteur Street, 02-093 Warsaw, Poland. s.goda@nencki.gov.pl
FAU - Piasecka, Joanna
AU  - Piasecka J
FAU - Olszewski, Maciej
AU  - Olszewski M
FAU - Kasicki, Stefan
AU  - Kasicki S
FAU - Hunt, Mark J
AU  - Hunt MJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130323
PL  - Germany
TA  - Psychopharmacology (Berl)
JT  - Psychopharmacology
JID - 7608025
RN  - 0 ((4-bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine)
RN  - 0 (Amphetamines)
RN  - 0 (Bridged Bicyclo Compounds)
RN  - 0 (CP-809,101)
RN  - 0 (Hallucinogens)
RN  - 0 (Methylamines)
RN  - 0 (Piperazines)
RN  - 0 (Pyrazines)
RN  - 0 (Receptor, Serotonin, 5-HT2A)
RN  - 0 (Serotonin Antagonists)
RN  - 0 (Serotonin Receptor Agonists)
RN  - 690G0D6V8H (Ketamine)
RN  - 8NA5SWF92O (Lysergic Acid Diethylamide)
RN  - OOM10GW9UE (4-iodo-2,5-dimethoxyphenylisopropylamine)
SB  - IM
MH  - Amphetamines/administration & dosage/*pharmacology
MH  - Animals
MH  - Bridged Bicyclo Compounds/administration & dosage/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Hallucinogens/administration & dosage/*pharmacology
MH  - Injections, Intraperitoneal
MH  - Ketamine/pharmacology
MH  - Lysergic Acid Diethylamide/administration & dosage/*pharmacology
MH  - Male
MH  - Methylamines/administration & dosage/pharmacology
MH  - Nucleus Accumbens/drug effects/metabolism
MH  - Piperazines/administration & dosage/pharmacology
MH  - Pyrazines/administration & dosage/pharmacology
MH  - Rats
MH  - Rats, Wistar
MH  - Receptor, Serotonin, 5-HT2A/*drug effects/metabolism
MH  - Serotonin Antagonists/pharmacology
MH  - Serotonin Receptor Agonists/administration & dosage/pharmacology
PMC - PMC3693439
EDAT- 2013/03/26 06:00
MHDA- 2014/02/11 06:00
PMCR- 2013/03/23
CRDT- 2013/03/26 06:00
PHST- 2012/08/23 00:00 [received]
PHST- 2013/02/11 00:00 [accepted]
PHST- 2013/03/26 06:00 [entrez]
PHST- 2013/03/26 06:00 [pubmed]
PHST- 2014/02/11 06:00 [medline]
PHST- 2013/03/23 00:00 [pmc-release]
AID - 3057 [pii]
AID - 10.1007/s00213-013-3057-1 [doi]
PST - ppublish
SO  - Psychopharmacology (Berl). 2013 Jul;228(2):271-82. doi: 
      10.1007/s00213-013-3057-1. Epub 2013 Mar 23.